« Top Headlines » Open DEMAT Account in 24 hrs  Income Tax Calculator FY 2023-24: How To Know Your Tax Liability Online On IT Dept's Portal?  BackBack Income Tax Act amendment on cards on tax treatment of MSME dues  ITR-1, ITR-2, ITR-4 forms for FY 2023-24 available for e-filing. Check details here  Income tax slabs FY 2024-25: Experts share these 8 benefits for taxpayers in new income tax regime  How To File ITR Online - Step by Step Guide to Efile Income Tax Return, FY 2023-24 (AY 2024-25)  Old or new tax regime for TDS on salary? This post-election 2024 event will impact your tax planning  What Are 5 Heads Of Income Tax?  Income Tax Dept releases interim action plan for FY25 on tax collection, refund approvals   Income Tax Return: 5 lesser-known tax-saving tips from Section 80  Income Tax Return: 5 lesser-known tax-saving tips from Section 80  Why you need not rush to file your ITR immediately «  CBEC puts recoverable indirect tax arrears at Rs 4,484 cr... Too preachy for the fin min’s taste... » Tax sops for pharma R&D may be extended September, 05th 2006 In order to promote continuous research and development (R&D) activities in the pharmaceuticals sector, the Ministry of Chemicals and Fertilisers has sought approval from the Finance Ministry for extending the time limit of tax exemptions provided for such activities. "Time limit for tax exemption on research and development oriented companies has been under consideration by the Ministry of Chemicals and Fertilisers. A proposal has been sent to the Revenue Department for the extension and we are hopeful for a favourable move," the secretary in the Department of Chemicals and Petrochemicals, Ms Satwant Reddy told reporters here. She said the time limit on tax incentives provided to R&D oriented companies was supposed to expire on March 31, 2007 and the Ministry wants to extend it by another 10 years up to 2017, she said. Pharmaceutical companies that fall under the Government's gold standard criteria are entitled to get the tax benefit under the existing R&D policy. Speaking at a symposium on Dynamics of Innovation Leadership in Knowledge Based Industries, she said that the challenges for development of R& D activities are to improve physical infrastructure, HRD and systematic changes in the regulatory and IPR regime.